Medicinal cannabis approvals through the Special Access Scheme fell to a nine-month low in January, preliminary data from the Therapeutic Goods Administration (TGA) has shown.

The regulator issued just under 8,800 SAS-B approvals, the lowest since April last year.

The vast majority, 7,300, were for Schedule 8 medicines, with S4 medicines making up the balance.

The  figures, taken from the TGA’s medicinal cannabis dashboard, gave oil a 55% share, with flower accounting for approximately one-third of applications.

Inhalation – which is now split out separately having barely registered for most of 2021 – accounted for almost 9%.

There were 715 authorised prescribers in January.

Almost 4,000 approvals came from Queensland, followed by Victoria with 2,270, New South Wales with 1,620 and Western Australia with 890.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...